Since the loss of ACE2 in COVID-19 supposedly leads to an imbalance of bradykinins, inhibition of the kallikrein-kinin system has been discussed as a treatment strategy in COVID-19 [46–48]. The gene discussed is ACE2; the disease is COVID-19.